Financials data is unavailable for this security.
View more
Year on year Cipla Ltd grew revenues 19.29% from 19.59bn to 23.36bn while net income improved 33.56% from 3.07bn to 4.10bn.
| Gross margin | 47.90% |
|---|---|
| Net profit margin | 17.64% |
| Operating margin | 22.16% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2005, Cipla Ltd increased its cash reserves by 146.32%, or 91.36m. The company earned 2.00bn from its operations for a Cash Flow Margin of 8.56%. In addition the company used 662.72m on investing activities and also paid 1.25bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | 258.16 |
| Book value per share | 0.6137 |
|---|---|
| Tangible book value per share | 0.6137 |
More ▼
Balance sheet in INRView more
| Current ratio | 2.25 |
|---|---|
| Quick ratio | 1.29 |
| Total debt/total equity | 0.1255 |
|---|---|
| Total debt/total capital | 0.1115 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 16.67% and 33.56%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 25.62% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
More ▼
